A phase IIIb, multinational, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease.

CB Celltech0 个研究点目标入组 500 人开始时间: 2007年10月31日最近更新: 2012年3月19日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 500

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Diagnosis of Crohn’s disease confirmed (at least 3 months prior to screening visit) by either radiological or endoscopic evidence. 2. Moderately to severely active Crohn’s disease (CDAI = 220 = 450) scored over the 7 days prior to the Baseline visit 3. No previous treatment with an anti-TNF agent 4. Male or female aged 18-75 years old 5. Are considered eligible according to the TB screening criteria. 6. Have screening laboratory results as follows: Serum Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) levels not exceeding 2 times the upper limit of normal for the central laboratory conducting the test. Serum creatinine not exceeding 1.7 mg/dl ( SI: = 150 mmol/L) Platelets = 100 x 103 cells/mL (SI: = 100 x 109 cells/L) Neutrophils = 1.5 x 103cells/mL (SI: = 1.5 x 109 cells/L) 7. Have met all the concomitant medication criteria in the table provided in the protocol. 8. Are capable of providing informed consent, which must be obtained prior to any study related procedures
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•1. Subject with Crohn’s disease who has perianal disease and/or any known fistulae 2. Subject with abscess or suspicion of abscess 3. Subject with symptomatic known obstructive strictures or bowel perforation in last 6 months 4. Subject with short bowel syndrome 5. Subject who has had a surgical bowel resection within the past 6 months or is planning any resection at time while enrolled in the study 6. Subject with current diagnosis of Ulcerative Colitis (UC) or Indeterminant Colitis as determined by investigator or Sponsor 7. Subject with ostomy or ileoanal pouch 8. Subject who is currently receiving total parenteral nutrition 9. Subject with positive stool cultures for enteric pathogens during screening (e.g. C. difficile) 10. Previous participation in a certolizumab pegol study 11. Subject who has received any investigational agent within 5 half-lives prior to study drug administration 12. Subject who has received any biologic product within 12 weeks prior to screening 13. Subject with any prior exposure to natalizumab (Tysabri) 14. Subject with a history of drug or alcohol abuse 15. Females who are pregnant or breast feeding 16. Females of child bearing age not practicing effective birth control 17. History of malignancy within last 5 years (except carcinoma –in situ of cervix or basal cell carcinoma that was successfully treated) 18. History or symptoms suggestive of lymphoproliferative disease as defined by unexplained lymphadenopathy and/or unexplained increase of white blood count of >20 x 109 cells/L 19. History of Human Immunodeficiency Virus (HIV), chronic or active Hepatitis B or Hepatitis C 20. History of Congestive Heart Failure (CHF), including medically controlled asymptomatic CHF 21. Has had a opportunistic infection (e.g. cytomegalovirus, pneumoncystis carii, aspergillosis, histoplasmosis, coccidioidomycosis) within 6 months prior to screening 22. Has had a serious infection, (e.g. pneumonia, sepsis, pyelonephritis), has been hospitalized for an infection, or has been treated with IV antibiotics for an infection within 3 months prior to screening. Less severe infections (acute upper respiratory tract infections, urinary tract infections) occurring in this timeframe need not be considered exclusionary at the discretion of the investigator and approval of the study physician. However subjects should not be enrolled when acutely ill with an intercurrent infection 23. Has a transplanted organ (except corneal transplant) 24. Has had a chest x-ray within 3 months prior to the first administration of study treatment that shows an abnormality suggestive of a malignancy or active infection, including TB 25. Has received or is expecting to receive, any live virus or bacterial vaccination within 3 months of first study drug administration, during the trial or 3 months after last dose of study drug 26. History of known demyelinating disease such as optic neuritis or multiple sclerosis 27. Has signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, psychiatric or cerebral disease.

研究者

发起方

CB Celltech

相似试验

进行中（未招募）

不适用

A phase IIIb, multinational, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s diseaseCrohn`s diseaseMedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's disease

EUCTR2007-001913-41-BECB Celltech550

进行中（未招募）

不适用

EUCTR2007-001913-41-CZCB Celltech550

进行中（未招募）

不适用

EUCTR2007-001913-41-EECB Celltech550

进行中（未招募）

不适用

A phase IIIb, multinational, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease.Crohn's diseaseMedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's disease

EUCTR2007-001913-41-ATCB Celltech550

进行中（未招募）

不适用

EUCTR2007-001913-41-FICB Celltech550